Whole-body MRI in paediatric oncology

Rutger A. J. Nievelstein1,2 · Annemieke S. Littooij1

Received: 7 October 2015 / Accepted: 27 October 2015 / Published online: 2 December 2015 © The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract Imaging plays a crucial role in the diagnosis and follow-up of paediatric malignancies. Until recently, computed tomography (CT) has been the imaging technique of choice in children with cancer, but nowadays there is an increasing interest in the use of functional imaging techniques like positron emission tomography and single-photon emission tomography. These later techniques are often combined with CT allowing for simultaneous acquisition of image data on the biological behaviour of tumour, as well as the anatomical localisation and extent of tumour spread. Because of the small but not negligible risk of radiation induced secondary cancers and the significantly improved overall survival rates of children with cancer, there is an increasing interest in the use of alternative imaging techniques that do not use ionising radiation. Magnetic resonance imaging (MRI) is a radiation-free imaging tool that allows for acquiring images with a high spatial resolution and excellent soft tissue contrast throughout the body. Moreover, recent technological advances have resulted in fast diagnostic sequences for whole-body MR imaging (WB-MRI), including functional techniques such as diffusion weighted imaging. In this review, the current status of the technique and major clinical applications of WB-MRI in children with cancer will be discussed.

Keywords MRI · Whole-body · Imaging · DWI · Paediatric oncology

Introduction

The recent technical developments in computed tomography (CT), magnetic resonance imaging (MRI) and nuclear medicine have changed the role of imaging in the evaluation of children with cancer revolutionary [1, 2]. In the past, imaging techniques have been mainly used as a tool to detect tumours and to assess the extent of tumour spread before and after therapy (i.e., structural imaging). But nowadays, it has also become possible to use imaging techniques to gain information on the biological behaviour of tumour, as well as the anatomical localisation and extent of tumour spread. Because of the small but not negligible risk of radiation induced secondary cancers and the significantly improved overall survival rates of children with cancer, there is an increasing interest in the use of alternative imaging techniques that do not use ionising radiation. Magnetic resonance imaging (MRI) is a radiation-free imaging tool that allows for acquiring images with a high spatial resolution and excellent soft tissue contrast throughout the body. Moreover, recent technological advances have resulted in fast diagnostic sequences for whole-body MR imaging (WB-MRI), including functional techniques such as diffusion weighted imaging. In this review, the current status of the technique and major clinical applications of WB-MRI in children with cancer will be discussed.
is an increasing interest in the use of alternative imaging techniques that do not use ionising radiation, such as ultrasonography (US) and MRI [1].

Although US is a child-friendly imaging technique that can provide real-time detailed images of most body parts, it is less useful for the evaluation of large masses, extended disease, deeper-lying tissues, and tissues located behind bones and air-containing tissues. That is why the main role of US in cancer imaging is to help ascertain the nature of palpable masses and to guide biopsy procedures. On the other hand, with MRI it is possible to acquire images with a high spatial resolution and excellent soft tissue contrast throughout the body, which makes it an ideal radiation-free tool for the detection of pathology, especially in parenchymal and bone marrow locations. Moreover, recent technological advances have resulted in fast diagnostic sequences for whole-body MR imaging (WB-MRI), including functional techniques such as diffusion weighted imaging (DWI) [3–10]. As a result, WB-MRI has become a clinically feasible imaging modality for staging and follow-up of malignancies in children [11–14]. This review will focus on the current status of the technique and major clinical applications of WB-MRI in children with cancer.

**Technique**

Until now, there is no standardised technique or protocol for performing WB-MRI [3, 6]. It usually involves imaging of the entire body (from vertex to toes) but in oncology, it is often restricted to the skull or skull base to groin region in line with most hybrid imaging techniques. Most modern MRI scanners are equipped with a moving table top for sequential movement of the patient through the magnet during imaging without the need for repositioning.

Regarding the choice of coils, the use of phased-array surface coils is preferred over the use of the quadrature body coil integrated in the magnet bore, because of the better spatial resolution and signal-to-noise ratio (SNR) of the first over the latter. This is especially true when functional imaging techniques like DWI are planned to be included in the imaging protocol. The way these coils can be used for whole-body image acquisition depends on the type of MRI scanner available. One approach, the so-called “sliding table and repositioning surface coil” approach, uses tabletop spacers to place an additional table platform on the original MR table allowing manipulation of the lower part of a non-integrated phased-array surface coil without repositioning the patient [15]. However, nowadays, on several modern MRI scanners dedicated multichannel surface coil systems are available allowing for whole-body imaging without the need to reposition the coil at each station [6].

Sequences that are typically used in WB-MRI include short tau inversion recovery (STIR), T1-weighted fast spin echo (FSE, TSE), and contrast material-enhanced (CE) T1-weighted three-dimensional gradient echo (VIBE, THRIVE, LAVA) sequences. STIR is the most commonly used sequence in WB-MRI because most pathologic tissues are proton rich with prolonged T1 and T2 relaxation times resulting in high signal intensity on STIR images. Furthermore, fat suppression on STIR images is more robust and homogeneous than on T2-weighted fat-saturated images. The T1-weighted FSE sequence is especially helpful for anatomic delineation of lesions and to increase the specificity of the detection of bone marrow involvement. The addition of a 3D CE T1-weighted GRE sequence will often improve the diagnostic accuracy of lesion delineation and characterization. Furthermore, it facilitates the combination of better local tumour staging and evaluation of metastatic disease.

With the introduction of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) in 2004 by Takahara et al., it became possible to perform whole-body DWI under free breathing within a clinically acceptable examination time [5, 7, 16, 17]. To improve lesion conspicuity high b-values of up to 1000 s/ mm² are applied and either a STIR pre-pulse or a frequency selective (chemical shift selective, CHESS) pre-pulse is used for fat suppression to optimise background body signal suppression. Note that fat suppression is also required to avoid image degradation due to severe chemical shift when using EPI. The choice of the method of fat suppression may depend on the organ/body region under examination, although STIR usually results in the most robust fat suppression over an extended field of view, in particular in the neck/shoulder region and lower extremities. In addition, if bowel signal suppression is an important issue, STIR is the preferred method in the abdominal region as well. In case quantitative measurements of the diffusivity (apparent diffusion coefficient, ADC) in pathological tissues are required, the use of at least three b-values is recommended (including b0).

The choice of scan plane will depend on the region of interest, type of malignancy, and diagnostic information required for optimal treatment planning and follow-up. However, the coronal plane is most often acquired and displayed in whole-body imaging, in particular when STIR and T1-weighted FSE sequences are used. The 3D CE T1-weighted GRE and DWIBS sequences are usually acquired in the axial plane, but the obtained images can be easily post-processed for multiplanar reconstruction (MPR) and maximum intensity projection (MIP). MRI of the thoracic and abdominal part of the body is challenging because of movement of patient respiration and bowel peristalsis. The anatomical imaging of thorax and abdomen
is usually obtained using respiratory compensation techniques, whereas the DWIBS imaging will take place under free breathing. To reduce the bowel motility, intravenously injection of an antiperistaltic agent can be considered, such as hyoscine butylbromide or glucagon. This is especially relevant if the abdomen is the site or predisposed area of the (known or suspected) primary malignancy.

In Tables 1 and 2 examples are given of two different WB-MRI protocols used in our centre for paediatric oncological indications.

### Clinical applications

#### Bone marrow imaging

Bone marrow has three primary components: osseous matrix, red marrow and yellow marrow. The osseous components provide supporting framework to the red and yellow marrow elements. The red marrow is composed of haematopoietic cells that produce the peripheral blood precursors, whereas in yellow marrow fat cells make up the vast majority. The distribution of haematopoietic marrow and its cellular content vary with age. At birth, marrow is entirely haematopoietic. Shortly after birth, the transition to yellow bone marrow occurs at an orderly and predictable sequence, which begins in the peripheral bones and progresses in a symmetrical manner to the central skeleton. Within the individual long bones, the marrow conversion occurs first in the diaphysis that progresses to the metaphysis. In the first decade of life the vertebral marrow is predominantly haematopoietic except for some yellow bone marrow around the central vertebral vein [18].

MRI is a sensitive method for assessing bone marrow; however, it lacks specificity. Normal bone marrow is rich in fat and water that together contribute to the signal seen on MRI. Red marrow contains approximately 40% fat and 40% water whereas yellow marrow is composed of approximately 80% fat and 15% water. TSE sequences allow superb differentiation between red and yellow bone marrow as the signal characteristics of fatty and hematopoietic marrow are different. However, the T1-weighted sequence will detect all the fat in the marrow inclusive the 40% fat that is present in the hematopoietic marrow. Therefore, hematopoietic marrow is slightly hyperintense to normal muscles and the intervertebral discs of the spine (Fig. 1b). On water sensitive images (i.e. STIR) hematopoietic marrow is of higher signal intensity than fatty marrow [3, 9].

Malignant infiltration of the bone marrow is associated with free water and oedema in addition to replacement of

| Table 1 WB-MRI protocol—lymphoma (1.5T, Ingenia, Philips Healthcare, Best, The Netherlands) |
|---------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Parameter                                  | T1-weighted TSE | STIR                    | DWI-STIR                    | T2-weighted SPAIR |
| Repetition time (ms)                       | 583             | 5231                    | 8046                        | 1250                       |
| Echo time (ms)                             | 18              | 65                      | 67                          | 80                          |
| Inversion time (ms)                        | –               | 165                     | 180                         | –                           |
| Receiver bandwidth (Hz)                    | 465.9           | 502.7                   | 57.3                        | 647.0                       |
| Slice orientation                          | Coronal         | Coronal                 | Axial                       | Axial                       |
| Slice thickness (mm)                       | 6.0             | 6.0                     | 4.0                         | 6.0                         |
| Slice gap (mm)                             | 1.0             | 1.0                     | 0                           | 0.7                         |
| No. of slices per station                  | 30              | 30                      | 60                          | 36                          |
| Cranio-caudal coverage per station         | 265             | 265                     | 240                         | 240                         |
| Field of view (mm²)                        | 530 × 265       | 530 × 265               | 450 × 365,625               | 450 × 366,4286             |
| Acquisition matrix                        | 208 × 287       | 336 × 133               | 128 × 82                    | 280 × 202                   |
| B-values (s/mm²)                           | –               | –                       | 0, 100, 800                 | –                           |
| No. of signal averaged                     | 1               | 1                       | 1                           | 1                           |
| Echo-planar imaging factor                 | –               | –                       | 41                          | –                           |
| Respiratory motion compensation technique  | Breath hold in thorax and abdomen | Breath hold in thorax and abdomen | Free breathing | Free breathing |
| Acquired voxel size (mm⁶)                  | 1.27 × 1.85 × 6.00 | 1.58 × 1.98 × 6.00 | 3.52 × 4.46 × 4.00 | 1.61 × 1.81 × 6.00 |
| Reconstructed voxel size (mm³)             | 1.04 × 1.04 × 6.00 | 1.04 × 1.04 × 6.00 | 2.01 × 1.99 × 4.00 | 0.94 × 0.93 × 6.00 |
| Effective scan time per station            | 54 s            | 1 min 45 s              | 4 min                       | 45 s                       |
| Total number of stations                   | 5               | 5                       | 4                           | 4                           |
| Total effective scan time                  | 4 min 30 s      | 8 min 45 s              | 16 min                      | 3 min                       |
the fatty content of normal marrow. Therefore, pathological bone marrow is of low T1 and high T2 signal (Fig. 1a). Especially in young patients it can be challenging to detect bone marrow disease, because the high cellularity of normal red marrow can be misdiagnosed as diffuse bone marrow infiltration or mask tumour deposits. Chemical shift imaging (oppose phase imaging) could be used as a complementary tool in order to differentiate between malignant bone marrow infiltration and normal red marrow by detecting small quantities of fat. Previous studies have shown that chemical shift imaging allows distinction between benign and malignant causes in adult patients [19, 20].

DWI in assessment of bone marrow disease is, especially in young patients, of limited value, as the high cellular haematopoietic marrow will exhibit impeded diffusion. Ording-Müller et al. [21] demonstrated that areas of restricted diffusion in the pelvic skeleton and lumbar spine are a normal finding in 48 % of healthy children. Therefore, DWI, if used in isolation, could increase the false-positive rate of bone marrow pathology.

Meyer et al. [22] tried to identify the best MRI sequence or image criteria for the diagnosis of bone marrow metastases in children with neuroblastoma. They found that homogenous low T1 signal had the highest sensitivity (88%), whereas a heterogeneous pattern on the post-gadolinium was highly specific (97%), but relatively insensitive (65%) for detecting metastasis.

### Malignant lymphoma

Lymphoma [Hodgkin Disease (HD) and non-Hodgkin lymphoma (NHL)] is the third most common form of malignancy in children, after leukaemia and brain tumours [23]. NHL is most frequent in children younger than 15 years

| Parameter | Pulse sequence |
|-----------|----------------|
| Repetition time (ms) | 454 | 5.5 | 1341 | 550 | 2000 | 5.5 |
| Echo time (ms) | 90 | 2.7 | 73 | 8.0 | 60 | 2.7 |
| Inversion time (ms) | – | – | – | – | 180 | – |
| Receiver bandwidth (Hz) | 570.1 | 309.6 | 47.9 | 206.1 | 383.0 | 309.6 |
| Slice orientation | Coronal | Axial | Axial | Sagittal | Sagittal | Axial |
| Slice thickness (mm) | – | – | – | – | 4.0 | 3.0 |
| Slice gap (mm) | – | – | – | – | 0.3 | 0.3 |
| No. of slices per station | 139 | 85 | 26 | 15 | 15 | 85 |
| Cranio-caudal coverage per station | 400 | 127.5 | 130 | 449.1228 | 448 | 127.5 |
| Field of view (mm²) | 400 × 354.023 | 250 × 189.2759 | 250 × 250 | 449.1228 × 160 | 448 × 160 | 250 × 189.2759 |
| Acquisition matrix | 348 × 308 | 232 × 185 | 88 × 70 | 228 × 494 | 160 × 381 | 232 × 185 |
| B-values (s/mm²) | – | – | 0, 100, 1000 | – | – | – |
| No. of signal averaged | 1 | 4 | 1 | 2 | 2 | 4 |
| Echo-planar imaging factor | – | – | 35 | – | – | – |
| Respiratory motion compensation technique | Respiratory triggered | Free breathing | Respiratory triggered | Free breathing | Free breathing | Free breathing |
| Acquired voxel size (mm³) | 1.15 × 1.15 × 1.15 | 1.08 × 1.07 × 3.00 | 2.84 × 3.57 × 5.00 | 0.70 × 0.91 × 3.00 | 1.00 × 1.17 × 3.00 | 1.08 × 1.07 × 3.00 |
| Reconstructed voxel size (mm³) | 0.83 × 0.83 × 1.15 | 0.74 × 0.74 × 1.50 | 1.74 × 1.74 × 5.00 | 0.47 × 0.47 × 3.00 | 0.70 × 0.70 × 3.00 | 0.74 × 0.74 × 1.50 |
| Effective scan time per station | 4 min 09 s | 2 min | 1 min 48 s | 5 min 10 s | 4 min | 2 min |
| Total number of stations | 1 | 3 | 3 | 1 | 1 | 3 |
| Total effective scan time | 4 min 09 s | 6 min | 5 min 24 s | 5 min 10 s | 4 min | 6 min |
whereas HD is predominantly diagnosed in teenagers. A major challenge in treating paediatric lymphoma is to optimise up-front treatment to prevent disease relapse, while minimising late therapy-related side effects. Accurate assessment of disease extent at diagnosis and response to treatment are therefore essential. Paediatric lymphomas are staged using the modified Ann Arbor and Murphy classifications for HD and NHL, respectively [24, 25].

Current guidelines encourage the use of FDG-PET/CT in staging and response assessment of FDG-avid lymphomas [24]. WB-MRI could be a good radiation-free alternative for staging and follow-up. Several studies have shown that WB-MRI is feasible, even in children (Fig. 2) [26–28]. Punwani et al. [27] reported very good agreement between WB-MRI compared to an FDG-PET/CT reference standard for nodal and extranodal disease, despite only using STIR for whole-body imaging.

There is an increased interest for the use of DWI in lymphoma due to the clear visualisation of the lymphoid tissue with DWI that is thought to increase the detection rate while decrease reading time. Lin et al. [29] showed an excellent agreement between WB-DWI and FDG-PET/CT in 15 adult patients with diffuse large B cell lymphomas. However, in other studies the additional value of DWI to conventional sequences could not be demonstrated [28, 30]. This could be related to the fact that both benign and malignant nodes demonstrate impeded diffusion. Also, there are no validated ADC values yet for discriminating involved from not involved sites [30]. Therefore, the detection of lymph nodes in WB-DWI is still based on size criteria. An important issue with DWI is that several normal extranodal structures (including brain, salivary glands, Waldeyer ring, thymus, spleen, gallbladder, adrenal glands, prostate, testes, penis, endometrium, ovaries, spinal cord, peripheral nerves and bone marrow) may demonstrate impeded diffusion. Consequently, pathology in any of these areas may be obscured.

Klenk et al. [14] prospectively compared Ferumoxytol-enhanced whole-body diffusion-weighted MRI to FDG-PET/CT in 22 children and young adults for staging lymphoma and sarcoma. This iron oxide contrast is thought to overcome the limitations of conventional WB-MRI regarding detecting bone marrow and splenic involvement. This better detection of lymphomatous involvement in the reticuloendothelial system (RES) depends on the uptake of USPIO through macrophages in the non-involved RES and the non-uptake by metastatic tumour deposits.

Assessment of response to therapy is important for determining treatment effectiveness and predicting clinical outcome. The concept of early response assessment

---

**Fig. 1** Sagittal T1 spin echo (SE) image in two patients diagnosed with neuroblastoma. **a** The image of a 3-year-old girl with proven bone marrow involvement illustrate the diffuse low signal intensity of the bone marrow of the spine compared to the intervertebral disk that is suggestive for diffuse bone marrow infiltration, whereas normal hematopoietic bone marrow is slightly hyperintense to the intervertebral discs of the spine at T1 weighted imaging. **b** The image of a 2-year-old girl with thoracic neuroblastoma shows the appearance of not-involved bone marrow within the vertebral bodies. **c** Transverse T2-W image demonstrates the intraspinal extension with spinal cord compression (arrow, see also the arrow in b) as well as the vascular encasement and the lifting of the aorta (arrowheads) that is considered one of the key imaging features of neuroblastoma.
with FDG-PET/CT in lymphoma has received considerable attention last years, however it is still not officially recommended outside clinical trials [24]. The role of WB-MRI in response assessment in children with lymphoma is still under investigation. Mayerhoefer et al. [31] recently published their results of their prospective study in 64 adult lymphoma patients that showed that WB-MRI with DWI could serve as a feasible alternative for FDG-PET/CT during follow-up and treatment response assessment. Several, mostly pilot, studies compared the quantitative data from FDG-PET/CT (SUV) with DWI (ADC values) for interim response assessment with inconclusive results. They reported presence or absence of an inverse correlation between ADC and SUV [32–35].

Although FDG-PET/CT is the imaging technique of choice for treatment response assessment, the value of interim and end-of-treatment FDG-PET/CT in predicting outcome was demonstrated to be unsatisfactory by recent meta-analyses [36, 37]. Therefore, prospective studies that correlate DWI results with patient outcome measures instead of FDG-PET/CT will provide reliable evidence.

**Histiocytosis**

Langerhans cell histiocytosis (LCH) is a rare disease that is characterised by lesions that include CD207+ dendritic cells with phenotypic similarity to epidermal Langerhans cells on a background of inflammatory cells [38]. The incidence of LCH is approximately 5:1,000,000 children younger than 15 years of age with an equal distribution among boys and girls. The median age of presentation is 30 months. LCH can involve almost any organ, and the most common presentation includes skin rashes and/or painful bone lesions. Less frequently, children present with diabetes insipidus due to pituitary involvement or back pain caused by vertebra plana. For prognostic purposes, patients are usually divided into a clinical “high-risk” versus “low-risk” group, based on the presence or absence of liver, spleen and/or bone marrow involvement. “High-risk” LCH patients have a >85% long-term survival rate, whereas the survival rate of “low-risk” LCH patients approaches 100%.

Adequate staging at diagnosis is essential, not only for determining prognosis, but also for choice of therapy, as lesions in more than one site usually impact the need for systemic chemotherapy. The standard approach to staging usually consists of a combination of laboratory tests and imaging [38, 39]. Traditionally, the imaging evaluation of patients with LCH includes chest radiography and a complete skeletal survey. Nowadays an abdominal ultrasound is usually added to rule out/demonstrate intra-abdominal organ involvement. Skeletal involvement is the most common radiographic abnormality in LCH. Primary sites of bony involvement are the skull, ribs, spine (vertebra plana), pelvis and scapula. The long bones are less frequently involved, with the femora as the most commonly involved long bone. Extension of the primary bony lesion in the surrounding soft tissues and epidural space can be seen, especially in the skull, ribs and spine. Bone scintigraphy has been used for the evaluation of LCH, and although lesion detection is usually higher when compared to the skeletal survey, the scintigraphic appearance of LCH may vary especially when the lesions are small or fail to incite a significant osteoblastic response [39, 40]. The use of 18F-FDG PET for the evaluation of paediatric LCH has been
reported, and several recent studies have shown high sensitivity and specificity of this imaging technique superior to the skeletal survey and bone scintigraphy [41]. In addition, 18F-FDG PET allows for the identification of extra-osseous localisations of LCH and shows lesion response to therapy earlier than conventional radiography and CT. However, a recent study by Mueller et al. [41] also showed that the overall sensitivity of 18F-FDG PET was lower than WB-MRI, especially for small bony infiltrates (mean diameter 12 mm), and central nervous system involvement. As stated before, WB-MRI is very well suited for the evaluation of bone marrow involvement, accompanying soft-tissue masses, and other extra-osseous manifestations. In LCH, most bony lesions will show intermediate–hypointense signal on T1-weighted images and hyperintense signal on T2-weighted and STIR images (Figs. 3, 4) [42, 43]. On postcontrast T1-weighted images the LCH lesions usually show marked enhancement although predominantly peripheral enhancement can be seen. In addition, early-stage lesions will show oedema in the adjacent bone marrow, periosteum and soft tissues. Direct extension in the adjacent soft tissues and epidural space is very well appreciated with MRI. The same holds true for the extra-osseous organ involvement. During treatment, healing lesions will show decrease in signal intensity on STIR imaging. Unfortunately, large prospective studies on the diagnostic accuracy of WB-MRI in paediatric LCH are missing. Goo et al. [42] compared the use of WB-MRI to conventional radiography and bone scintigraphy in 9 children with LCH. Additional skeletal lesions were identified by WB-MRI in 3 out of 8 patients compared with plain radiography (38 %), and in 2 out of 8 patients compared with scintigraphy (25 %). Furthermore, WB-MRI detected extra-osseous lesions in 5 of nine patients exclusively (56 %). Steinborn et al. [43] did investigate the use WB-MRI in 6 children with LCH at diagnosis and during follow up. In comparison with the skeletal survey, WB-MRI did detect additional lesions in two patients, which resulted in a change of therapy in both children. On the other hand, Mueller et al. [41] did show that, although WB-MRI was more sensitive for the detection of LCH lesions when compared 18F-FDG-PET, specificity was significantly lower (67 and 76 % for PET

Fig. 3 14-year-old male with Langerhans cell histiocytosis (LCH) presenting with a painless swelling on the skull. Axial proton density weighted image (a), T2-weighted image (b), and sagittal T1-weighted images before (c) and after the administration of intravenous contrast material (d). The lesion shows almost homogeneous T2 hyperintensity and slightly heterogeneous T1 intermediate signal intensity (arrow in a–c). After contrast material administration there is a predominantly peripheral enhancement pattern, less often seen in LCH lesions (arrow in d)
vs. 81 and 47 % for WB-MRI). The lower specificity of WB-MRI was mainly due to the detection of false-positive bone lesions. Furthermore, residual T2 hyperintensity and contrast-enhancement after treatment on WB-MRI resulted in false-positive findings during follow-up. Interestingly, a combined analysis of PET and MRI decreased the number of false-negative findings at primary staging, whereas no advantage over PET alone was seen in terms of false-positive or false-negative results during follow-up.

Neuroblastoma

Neuroblastoma (NBL) is the most common solid extra-cranial tumour in children and infants. It represents approximately 6 % of all cases of childhood cancer and accounts for 15 % of cancer deaths in children [23]. NBL is an embryonic tumour arising from primordial neural crest cells that are the precursors of the sympathetic nervous system. The most common site of the primary tumour is within the abdomen (the adrenal medulla in 35 %), but it can occur anywhere along the sympathetic chain from neck to pelvis [44]. Nearly 70 % of children with NBL will have metastatic disease at diagnosis (cortical bone, bone marrow, lymph nodes, liver and skin). NBLs have a variable prognosis. Some tumours behave aggressively, while others, often in the younger age group, may spontaneously regress [44].

Ninety percentage of patients are diagnosed before the age of 6, with a peak incidence around 2–3 years [44]. Clinical presentation varies with the size, spread and location of the tumour in often an unwell child. In the abdomen it can cause abdominal distension, sometimes nausea or pain. Unexplained fevers, bone pain or limping is caused by bone or bone marrow involvement. If the tumour is compressing the spinal cord it causes muscle weakness or problems with urinating or defecation. Some tumours produce hormones that can cause high blood pressure, increased heart rate, flushing or diarrhoea.

Since 1986, the International Neuroblastoma Staging System (INSS) has been used as a post-surgical staging system. In 2009 a new staging system was published [the International Neuroblastoma Risk Group Staging System (INRGSS)], shifting focus to pre-treatment staging with identification of imaging defined risk factors (IDRF) [45]. These IDRFs describe the relationship between the tumour and adjacent structures that ideally should not be injured during surgery (i.e., major vascular encasement, airway compression or CNS infiltration).

The combination of nuclear medicine and radiological examinations are crucial for accurate staging, defining resectability and follow-up during treatment. Traditionally, CT, I-123 MIBG scintigraphy and bone marrow biopsies were used to evaluate the local and distant extent of disease. However, MRI is increasingly used for anatomical...
imaging (Fig. 5) [44]. The impact of WB-MRI in neuroblastoma has not been thoroughly evaluated. Pluger et al. [46] retrospectively reviewed 50 MRI and I-123 MIBG examinations in 28 patients for the assessment of neuroblastoma lesions at presentation and follow-up. They concluded that integrated imaging with I-123 MIBG scintigraphy and MRI increased the diagnostic accuracy. Gahr et al. [47] studied the role of DWI in differentiating neuroblastoma and ganglioneuroblastoma/ganglieneuroma in 15 patients with 16 histologically classified tumours. They found that there was a significant difference in ADC between neuroblastoma and ganglioneuroblastoma/ganglieneuroma. However, the inter- and intraobserver variability of their applied method was not tested. Besides, there was a considerable overlap in ADC values between these groups.

Cancer predisposition syndromes

WB-MRI is a promising imaging tool in the evaluation of genetic cancer predisposition syndromes (CPS), especially because of its lack of ionising radiation [48, 49]. Children with CPS (including neurofibromatosis type 1, Beckwith-Wiedemann, multiple endocrine neoplasia, Li-Fraumeni, Von Hippel-Lindau, and rhabdoid tumour syndrome) are at a significantly increased risk of developing cancer, but when and in which organs tumours will develop is difficult to predict. Therefore, screening on a regularly basis is usually recommended in these children, the frequency of which depends on the specific syndrome and risk stratification. Several publications already did mention the use of WB-MRI as a screenings method in CPS, but studies on the performance of this technique in children is scarce. Friedman et al. [48] retrospectively investigated the role of WB-MRI as a screening tool in follow-up of children and adolescents with hereditary retinoblastoma. WB-MRI detected suspicious lesions in 5 of 25 patients during follow-up of which only 2 appeared to be malignant (osteosarcoma). One additional patient was diagnosed with osteosarcoma 3 months after a normal WB-MRI. The sensitivity of WB-MRI to detect subsequent malignant lesions in this specific patient group was 66.7 % and the specificity 92.1 %. Another recent (retrospective) study, which included 50 WB-MRI examinations in 24 children with genetic CPS, did show that WB-MRI is a valuable screening tool with a high sensitivity of 100 % (95 % CI 6–100 %), specificity of 94 % (82–98 %), and negative predictive value of 94 % (90–100 %) [49]. In nine of the 50 WB-MRI examinations a suspicious lesion was found; 2 high-risk, 2 moderate-risk, and 5 low-risk lesions. Of the 4 high- to moderate-risk lesions, only one lesion appeared to be malignant resulting in a positive predictive value of only 25 % (95 % CI 1–78 %). The other lesions and all low-risk lesions had a benign origin. Of interest, this study did also show that incidental findings were detected in 23 of 24 patients, most of which did not require imaging follow-up. Finally, all abnormalities were best detected on the (fluid-sensitive) STIR images. The role of DWI has not been investigated. Both studies conclude that, although WB-MRI can be regarded as a valuable screening tool, larger cohort studies are needed to validate its role and cost-effectiveness in this specific group of patients. Furthermore, Anupindi et al. [49] recommend that interpretation of these studies should be reserved to radiologists that are familiar with WB-MRI to appropriately risk stratify abnormalities and minimise unnecessary interventions.

Future perspectives

In children, the choice of imaging modality is driven mainly by reducing the radiation dose as much as possible. This also accounts for children with cancer, as their overall survival rates have increased significantly over the past decades. This explains the increasing interest for the use of (whole-body) MRI in the diagnostic work-up and follow-up of children with cancer. As illustrated in this review, WB-MRI is already widely used in paediatric oncology, despite the fact that validation of the technique is mainly based on retrospective data in relatively small patient groups. There is a strong need for large prospective cohort studies to better validate the role and cost-effectiveness of WB-MRI in children with cancer, both for diagnosis as well as therapy response assessment. However, due to the comparatively low incidence of most paediatric malignancies, most institutions will not have sufficient patient volume to perform clinical trials that will result in definitive and statistically significant data. This obviates the need for increasing international multi-institutional collaboration and set up of multicentre clinical trials [50].

In oncology, the role of imaging is moving from structural (anatomic) imaging to combined structural and functional (molecular) imaging, enabling better tumour characterization, prognostication, response assessment, and prediction of outcome of therapy. That is why research on WB-MRI in children not only should focus on further optimization of anatomic sequences (including reduction of scan duration) but also on the introduction and validation of new functional techniques. DWI is already widely used, but the value of DWI and ADC measurements in diagnosis and follow up still has to be validated. Other functional techniques focus on tumour vascularisation, such as dynamic contrast-enhanced MRI (DCE-MRI) and arterial spin labelling (ASL). A major advantage of ASL over DCE-MRI is that it does not need intravenous contrast material injection, which makes it an ideal tool for children. Magnetic resonance spectroscopy (MRS) allows for a non-invasive separation of the MRI signal from a given tissue
Fig. 5 A 4-year-old girl diagnosed with stage IV neuroblastoma. Coronal acquired 3D T2-weighted image (a) with axial reconstruction (c) demonstrates the primary tumour arising from the left adrenal gland (arrows) with compression upon the left kidney, vascular encasement and lifting of the aorta (arrowhead). The post-contrast T1-weighted image illustrates heterogeneous enhancement (b). There is diffusion restriction seen as high signal at the b1000 image (d) with corresponding low signal at the ADC map (e).
into its different chemical components, which may improve lesion characterization and prediction of clinical outcome. Although ASL and MRS are already established techniques in neuroradiology, their possible role in (paediatric) malignancies outside the brain has to be validated yet. In this scope, the recent development of integrated PET/MRI systems is very interesting, combining the superior structural imaging of MRI with the functional (molecular) information of both imaging techniques while decreasing the radiation dose. Although the first publications in children show promising results, it currently remains a technical challenge to construct and use these hybrid systems [51–53].

Conclusion

WB-MRI is a very promising and already widely used imaging technique in paediatric oncology. This is mainly due to the lack of ionising radiation, its superior tissue contrast and potential to non-invasively generate functional information on tumour biology. It provides complementary information to the increasingly used molecular imaging techniques like PET/CT and SPECT/CT. However, there is still a strong need for prospective large cohort studies to better validate the role and cost-effectiveness of WB-MRI in paediatric oncology.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical standards This article does not contain any studies with human participants or animals performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Goo HW (2011) Regional and whole-body imaging in pediatric oncology. Pediatr Radiol 41(Suppl 1):S186–S194
2. Uslu L, Donig J, Link M, Rosenberg J, Quon A, Daldrup-Link HE (2015) Value of 18F-FDG PET and PET/CT for evaluation of pediatric malignancies. J Nucl Med 56(2):274–286
3. Darge K, Jaramillo D, Siegel MJ (2008) Whole-body MRI in children: current status and future applications. EJR 68:289–298
4. Ley S, Ley-Zaporozhan J, Schenk JP (2009) Whole-body MRI in the pediatric patient. EJR 70:442–451
5. Kwec TC, Takahara T, Vermoolen MA, Bierings MB, Mali WP, Nievelstein RA (2010) Whole-body diffusion-weighted imaging for staging malignant lymphoma in children. Pediatr Radiol 40(10):1592–1602
6. Chavhan GB, Babyn PS (2011) Whole body MR imaging in children: principles, technique, current applications, and future directions. Radiographics 31:1757–1772
7. Padhani AR, Koh DM, Collins DJ (2011) Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 261:700–718
8. Smith EA (2013) Advanced techniques in pediatric abdominopelvic oncologic magnetic resonance imaging. Magn Reson Imaging Clin N Am 21:829–841
9. Akin KL, Ditchfield MR (2014) The role of whole-body MRI in pediatric oncology. J Pediatr Hematol Oncol 36:342–352
10. Canale S, Vilicot L, Ammari S, Lemery M, Bidault F, Balleyguier C, Caramella C, Dromain C (2014) Whole body MRI in paediatric oncology. Diagn Interv Imaging 95:541–550
11. Goo HW, Choi SH, Ghim T, Moon HN, Seo JJ (2005) Whole-body MRI of paediatric malignant tumours: comparison with conventional oncological imaging methods. Pediatr Radiol 35:766–773
12. Siegel MJ, Acharyya S, Hoffer FA, Wylly JB, Friedmann AM, Snyder BS, Babyn PS, Khanna G, Siegel BA (2013) Whole-body MR imaging for staging of malignant tumours in pediatric patients: results of the American College of Radiology Imaging Network 6660 Trial. Radiology 266:599–609
13. Kembhavi SA, Rangarajan V, Shah S, Qureshi S, Arorad B, Juvekar S, Laskar S, Vora T, Chinnaswamy G, Ramadwar M, Kurkure P (2014) Prospective observational study on diagnostic accuracy of whole-body MRI in solid small round cell tumours. Clin Radiol 69:900–908
14. Klenk C, Gawande R, Uslu L, Khurana A, Qiu D, Quon A, Doig J, Rosenberg J, Luna-Fineman S, Moseley M, Daldrup-Link HE (2014) Ionising radiation-free whole-body MRI versus 18F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. Lancet Oncol 15:275–285
15. Takahara T, Kwee TC, Kifune S, Ochii R, Sakamoto T, Niwa T, Van Cauteren M, Luijten PR (2010) Whole-body MRI using a sliding table and repositioning surface coil approach. Eur Radiol 20:1366–1373
16. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22(4):275–282
17. Vilanova JC, Barcelo J (2008) Diffusion-weighted whole-body MR screening. EJR 67:440–447
18. Laor T, Jaramillo D (2009) MR imaging insights into skeletal maturation: what is normal? Radiology 250(1):28–38
19. Disler DG, McCauley TR, Ratner LM et al (1997) Imaging of bone marrow: prediction of neoplasia based on the detection of coexistent fat and water. AJR 169:1439–1447
20. Zajick DCJ, Morrison WB, Schweitzer ME et al (2005) Benign and malignant processes: normal values and differentiation with chemical shift MR imaging in vertebral marrow. Radiology 237:590–596
21. Ording-Müller LS, Avenarius D, Olsen OE (2011) High signal in bone marrow at diffusion-weighted imaging with background suppression (DWIBS) in healthy children. Pediatr Radiol 41(2):221–226
22. Meyer JS, Siegel MJ, Faroqui SO, Jaramillo D, Fletcher BD, Hoffer FA (2005) Which MRI sequence of the spine best reveals bone-marrow metastases of neuroblastoma? Pediatr Radiol 35(8):778–785
23. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29
24. Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068

25. Johnson SA, Kumar A, Matasar MJ, Schöder H, Rademaker J (2015) Imaging for staging and response assessment in lymphoma. Radiology 276(2):323–338

26. Kellenberger CJ, Miller SF, Khan M, Gilday DL, Weitzman S, Babyn PS (2004) Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children. Eur Radiol 14(10):1829–1841

27. Punwani S, Taylor SA, Bainbridge A et al (2010) Pediatric and adolescent lymphoma: comparison of whole-body STIR half-Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging. Radiology 255(1):182–190

28. Littooyi AS, Kwee TC, Barber I et al (2014) Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard. Eur Radiol 24(5):1153–1165

29. Lin C, Luciani A, Itti E et al (2010) Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol 20(8):2027–2038

30. Kwee TC, Takahara T, Luijten PR, Nievelstein RA (2010) ADC measurements of lymph nodes: inter- and intra-observer reproducibility study and an overview of the literature. Eur J Radiol 75(2):215–220

31. Mayerhoefer ME, Karanikas G, Kletter K et al (2015) Evaluation of diffusion-weighted magnetic resonance imaging for follow-up and treatment response assessment of lymphoma: results of an 18F-FDG-PET/CT-controlled prospective study in 64 patients. Clin Cancer Res 21(11):2506–2513

32. Punwani S, Prakash V, Bainbridge A et al (2010) Quantitative diffusion weighted MRI: a functional biomarker of nidal disease in Hodgkin lymphoma? Cancer Biomark 7(4):249–259

33. Lin C, Itti E, Luciani A et al (2011) Whole-body diffusion-weighted imaging with apparent diffusion coefficient mapping for treatment response assessment in patients with diffuse large B-cell lymphoma: pilot study. Invest Radiol 46(5):341–349

34. Punwani S, Taylor SA, Saad ZZ et al (2013) Diffusion-weighted MRI of lymphoma: prognostic utility and implications for PET/MRI? Eur J Nucl Med Mol Imaging 240(3):373–385

35. Wu X, Pertovaara H, Dastidar P, Vornanen M, Paavolainen L, Järvenpää R, Eskola H, Kellokumpu-Lehtinen PL (2013) ADC measurements in diffuse large B-cell lymphoma and follicular lymphoma: a DWI and cellularity study. Eur J Radiol 82:e158–e164

36. Sun N, Zhao J, Qiao W, Wang T (2015) Predictive value of interim PET/CT in DLBCL treated with R-CHOP: meta-analysis. Biomed Res Int 2015:648572. doi:10.1155/2015/648572

37. Adams JH, Nievelstein RA, Kwee TC (2015) Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis. Br J Haematol 170(3):356–366

38. Allen CE, Kelly KM, Bollard CM (2015) Pediatric lymphomas and histiocytic disorders of childhood. Pediatr Clin N Am 62:139–165

39. Azouz EM, Saigal G, Rodriguez MM, Podda A (2005) Langerhans’ cell histiocytosis: pathology, imaging and treatment of skeletal involvement. Pediatr Radiol 35:103–115

40. Van Nieuwenhuys JP, Clapuyt P, Malghem J, Everarts P, Melin J, Pauwels S, Brichard B, Ninane J, Vennynen C, Cornu G (1996) Radiographic skeletal survey and radionuclide bone scan in Langerhans cell histiocytosis of bone. Pediatr Radiol 26(10):734–738

41. Mueller WP, Melzer HI, Schmid I, Coppenrath E, Bartenstein P, Pfluger T (2013) The diagnostic value of 18F-FDG PET and MRI in paediatric histiocytosis. Eur J Nucl Med Mol Imaging 40:356–363

42. Goo HW, Yang DH, Ra YS, Song JS, Im HJ, Seo JJ, Ghim T, Moon HN (2006) Whole-body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy. Pediatr Radiol 36:1019–1031

43. Steinborn M, Wörüller K, NathrauthM Schöninger M, Hahn H, Rummeny EJ (2008) Whole-body MRI in children with Langerhans cell histiocytosis for the evaluation of the skeletal system. RoFo 180:646–653

44. Papaoaounou G, McHugh K (2005) Neuroblastoma in childhood: review and radiological findings. Cancer Imaging 5:116–127

45. Monclair T, Brodeur GM, Ambros PF et al (2009) The International Neuroblastoma Risk Group (INRG) staging system: an INRG task force report. J Clin Oncol 27(2):298–303

46. Pfluger T, Schmied C, Porn U et al (2003) Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. AJR Am J Roentgenol 181(4):1115–1124

47. Gahr N, Darge K, Hahn G, Kreher BW, von Buiren M, Uhl M (2011) Diffusion-weighted MRI for differentiation of neuroblastoma and ganglioneuroblastoma/ganglioneuroma. Eur J Radiol 79(3):443–446

48. Friedlman DN, Lis E, Sklar CA, Oeffinger KC, Reppucci M, Fleischut MH, Francis JH, Marr B, Abramson DH, Dunkel JJ (2014) Whole-body magnetic resonance imaging (WB-MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: a pilot study. Pediatr Blood Cancer 61(8):1440–1444

49. Anupindi SA, Bedoya MA, Lindell RB, Rambhatla SJ, Zelley K, Nichols KE, Chauvin NA (2015) Diagnostic performance of whole-body MRI as a tool for cancer screening in children with genetic cancer-predisposing conditions. AJR 205:400–408

50. Offiah AC, Andronikou S, Avni F, Daltro P, Donnelly LF, Jaramillo D, Kim IO, Nievelstein RA, Owens CM, Slotos TL, van Rijn R, Lee EY (2014) Expert opinion: what are the greatest challenges and barriers to applying evidence-based and practical approaches to preclinical and clinical research in the field of pediatric radiology? Pediatr Radiol 44(10):1209–1212

51. Hirsch FW, Sattler B, Sorge J, Kurch L, Viehweger A, Ritter L, Schäfer JF, Gatidis S, Schmidt H, Gückel B, Bezrukov I, Pfannenberg CA, Reimold M, Ebinger M, Fuchs J, Claussen CD, Schwenzer NF (2014) Simultaneous whole-body PET/MR in children: initial clinical experience in paediatric oncology using an integrated PET/MR scanner. Pediatr Radiol 43:860–875

52. Eiber M, Takei T, Souvatzoglou M, Mayerhoefer ME, Fürt S, Gaertner FC, Loefelbein DJ, Rummeny EJ, Ziegler SI, Schweiger M, Beer AJ (2014) Performance of whole-body integrated imaging in comparison to PET/CT in pediatric oncology: initial results. Pediatr Radiol 34(10):1267–1276.

53. Papaioannou G, McHugh K (2005) Neuroblastoma in childhood: review and radiological findings. Cancer Imaging 5:116–127

54. Monclair T, Brodeur GM, Ambros PF et al (2009) The International Neuroblastoma Risk Group (INRG) staging system: an INRG task force report. J Clin Oncol 27(2):298–303

55. Offiah AC, Andronikou S, Avni F, Daltro P, Donnelly LF, Jaramillo D, Kim IO, Nievelstein RA, Owens CM, Slotos TL, van Rijn R, Lee EY (2014) Expert opinion: what are the greatest challenges and barriers to applying evidence-based and practical approaches to preclinical and clinical research in the field of pediatric radiology? Pediatr Radiol 44(10):1209–1212

56. Hirsch FW, Sattler B, Sorge J, Kurch L, Viehweger A, Ritter L, Werner P, Jochimsen T, Barthel B, Bierbach U, Till H, Sabri O, Kluge R (2013) PET/MR in children: initial clinical experience in pediatric oncology using an integrated PET/MR scanner. Pediatr Radiol 43:860–875

57. Eiber M, Takei T, Souvatzoglou M, Mayerhoefer ME, Fürt S, Gaertner FC, Loefelbein DJ, Rummeny EJ, Ziegler SI, Schweiger M, Beer AJ (2014) Performance of whole-body integrated imaging in comparison to PET/CT in pediatric oncology: initial results. Pediatr Radiol 34(10):1267–1276.